Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lagociclovir valactate

Drug Profile

Lagociclovir valactate

Alternative Names: 204937; DWP 10019; MIV-210

Latest Information Update: 09 Sep 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Developer Daewoong Pharmaceutical; Medivir AB
  • Class Antivirals; Lactates; Purine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; HIV infections

Most Recent Events

  • 06 Sep 2013 Discontinued - Phase-I for Hepatitis B in South Korea (PO)
  • 06 Sep 2013 Discontinued - Phase-I for Hepatitis B in United Kingdom (PO)
  • 31 Dec 2012 Phase I development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top